Brigham MS | CLIMB Study Brigham MS | CLIMB Study Brigham MS | CLIMB Study

Comprehensive Longitudinal Investigation of Multiple Sclerosis (CLIMB Study) at Brigham and Women's Hospital

The CLIMB study is a large-scale, long-term study of patients with MS. It is designed to investigate the course of the disease in the current era of treatment. The main goals of the study are to:

  1. Identify predictors of future disease course when patients are at the beginning of their illness.
  2. Determine the effects of treatment on disease progression and accumulation of disability.

Subjects will have neurological exams and MRI yearly. Subjects will also donate blood samples and complete quality of life and mood questionnaires yearly.

Eligible subjects are those with:

  1. Diagnosis of MS or monosymptomatic disease
  2. 18 years of age or older
  3. Willing to have MRI yearly
  4. Willing to donate blood samples and complete questionnaires yearly

If you would like to learn more about the CLIMB Study, please email

CLIMB Study Research Team

CLIMB investigators have contributed to 195 publications as of August 2023


  1. Lesion network localization of depression in multiple sclerosis. Siddiqi SH, Kletenik I, Anderson MC, Cavallari M, Chitnis T, Glanzi BI, Khalil S, Palotai M, Bakshi R, Guttmann CRG, Fox MD. Nature Mental Health 1, 36–44 (2023).
  2. Exploring the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis. AbdelRazek MA, Tummala S, Khalid F, Tauhid S, Jalkh Y, Khalil S, Hurwitz S, Zurawski J, Bakshi R. Journal of the Neurological Sciences. 2023;444:120501. doi:
  3. Early miR-320b and miR-25-3p miRNA levels correlate with multiple sclerosis severity at 10 years: a cohort study. Gonzalez-Martinez A, Bose G, Lokhande H, Saxena S, Healy BC, Polgar-Turcsanyi M, Weiner HL, Chitnis T. J Neuroinflammation. 2023 Jun 1;20(1):136. doi: 10.1186/s12974-023-02816-8. PMID: 37264432; PMCID: PMC10233999.
  4. Do clinical trials prepare to fail by failing to prepare? An examination of MS trials and recommendations for patient-reported outcome measure selection. Hobart J, Chitnis T, Oh J, Burke L, King M, Vo P, Vandercappellen J, Lloyd A. Mult Scler Relat Disord. 2023 Jun 7;76:104788. doi: 10.1016/j.msard.2023.104788. [Epub ahead of print] Review. PMID: 37327599; not federally funded.
  5. Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes. Bose G, Healy BC, Saxena S, Saleh F, Paul A, Barro C, Lokhande HA, Polgar-Turcsanyi M, Anderson M, Glanz BI, Guttmann CRG, Bakshi R, Weiner HL, Chitnis T. Mult Scler Relat Disord. 2023 Jun;74:104695. doi: 10.1016/j.msard.2023.104695. Epub 2023 Apr 2. PMID: 37060852; PMC pending.
  6. miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod. Gonzalez-Martinez A, Patel R, Healy BC, Lokhande H, Paul A, Saxena S, Polgar-Turcsanyi M, Weiner HL, Chitnis T. J Neuroinflammation. 2023 May 30;20(1):131. doi: 10.1186/s12974-023-02811-z. PMID: 37254147; PMCID: PMC10227972.
  7. Analytical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis. Qureshi F, Hu W, Loh L, Patel H, DeGuzman M, Becich M, Rubio da Costa F, Gehman V, Zhang F, Foley J, Chitnis T. Proteomics Clin Appl. May;17(3):e2200018. doi: 10.1002/prca.202200018. Epub 2023 Mar 20. PMID: 36843211; not federally funded.
  8. Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine. Conway S, Saxena S, Baecher-Allan C, Krishnan R, Houtchens M, Glanz B, Saraceno TJ, Polgar-Turcsanyi M, Bose G, Bakshi R, Bhattacharyya S, Galetta K, Kaplan T, Severson C, Singhal T, Stazzone L, Zurawski J, Paul A, Weiner HL, Healy BC, Chitnis T. Mult Scler J Exp Transl Clin. 2023 Apr-Jun;9(2):20552173231165196. doi: 10.1177/20552173231165196. eCollection 2023 Apr-Jun. PMID: 37057191; PMCID: PMC10086198.
  9. Nasal administration of anti-CD3 mAb (Foralumab) downregulates NKG7 and increases TGFB1and GIMAP7 expression in T cells in subjects with COVID-19. G Moreira T, Gauthier CD, Murphy L, Lanser TB, Paul A, Matos KTF, Mangani D, Izzy S, Rezende RM, Healy BC, Baecher-Allan CM, Chitnis T, Kuchroo V, Weiner HL. Proc Natl Acad Sci U S A. 2023 Mar 14;120(11):e2220272120. doi: 10.1073/pnas.2220272120. Epub 2023 Mar 7. PMID: 36881624; PMCID: PMC10243127.
  10. Fronto-striatal damage may contribute to resistance to fatigue-lowering medications in multiple sclerosis. Palotai M, Pintye D, Glanz B, Chitnis T, Guttmann CRG. J Neuroimaging. 2023 Mar;33(2):269-278. doi: 10.1111/jon.13082. Epub 2023 Feb 6. PMID: 36746670; not federally funded.
  11. Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients. Barro C, Healy BC, Saxena S, Glanz BI, Paul A, Polgar-Turcsanyi M, Guttmann CR, Bakshi R, Weiner HL, Chitnis T. Mult Scler. 2022 Nov 30:13524585221137697. doi: 10.1177/13524585221137697. Epub ahead of print. PMID: 36448331.
  12. Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis. Barro C, Healy BC, Liu Y, Saxena S, Paul A, Polgar-Turcsanyi M, Guttmann CRG, Bakshi R, Kropshofer H, Weiner HL, Chitnis T. Neurol Neuroimmunol Neuroinflamm. 2022 Nov 14;10(1):e200052. doi: 10.1212/NXI.0000000000200052. PMID: 36376097; PMCID: PMC9749933.
  13. Anti-CGRP therapies for migraine in multiple sclerosis patients. Mult Scler. Gonzalez-Martinez A, Bose G, Chitnis T.  2022 Nov;28(13):2149-2150. doi: 10.1177/13524585221096353. Epub 2022 May 14.  PMID: 35575242; not federally funded.
  14. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes. Holroyd KB, Healy BC, Conway S, Houtchens M, Bakshi R, Bhattacharyya S, Bose G, Galetta K, Kaplan T, Severson C, Singhal T, Stazzone L, Zurawski J, Polgar-Turcsanyi M, Saxena S, Paul A, Glanz BI, Weiner HL, Chitnis T.  Mult Scler Relat Disord. 2022 Nov;67:104079. doi: 10.1016/j.msard.2022.104079. Epub 2022 Jul 28.  PMID: 35952457; PMCID: PMC9330583.
  15. Clinical Trial-Ready Patient Cohorts for Multiple System Atrophy: Coupling Biospecimen and iPSC Banking to Longitudinal Deep-Phenotyping. Ndayisaba A, Pitaro AT, Willett AS, Jones KA, de Gusmao CM, Olsen AL, Kim J, Rissanen E, Woods JK, Srinivasan SR, Nagy A, Nagy A, Mesidor M, Cicero S, Patel V, Oakley DH, Tuncali I, Taglieri-Noble K, Clark EC, Paulson J, Krolewski RC, Ho GP, Hung AY, Wills AM, Hayes MT, Macmore JP, Warren L, Bower PG, Langer CB, Kellerman LR, Humphreys CW, Glanz BI, Dielubanza EJ, Frosch MP, Freeman RL, Gibbons CH, Stefanova N, Chitnis T, Weiner HL, Scherzer CR, Scholz SW, Vuzman D, Cox LM, Wenning G, Schmahmann JD, Novak P, Young GS, Feany MB, Singhal T, Khurana V. Cerebellum. 2022 Oct 3;. doi: 10.1007/s12311-022-01471-8. [Epub ahead of print] PMID: 36190676; PMCID: PMC9527378.
  16. Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course. iMSMS Consortium. Electronic address:; iMSMS Consortium. Cell. 2022 Sep 15;185(19):3467-3486.e16. doi: 10.1016/j.cell.2022.08.021. PMID: 36113426.
  17. Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis. Cohen JA, Lublin FD, Lock C, Pelletier D, Chitnis T, Mehra M, Gothelf Y, Aricha R, Lindborg S, Lebovits C, Levy Y, Motamed Khorasani A, Kern R. Mult Scler. 2022 Sep 14;:13524585221122156. doi: 10.1177/13524585221122156. [Epub ahead of print] PMID: 36113170; not federally funded.
  18. Estimating the association between physical activity and health-related quality of life in individuals with multiple sclerosis. Healy BC, Casady EC, Chitnis T, Weiner HL, Glanz BI. Mult Scler Relat Disord. 2022 Sep;65:104006. doi: 10.1016/j.msard.2022.104006. Epub 2022 Jul 2. PMID: 35816952; not federally funded.
  19. Younger age at multiple sclerosis onset is associated with worse outcomes at age 50. Bose G, Healy BC, Barro C, Glanz BI, Lokhande HA, Polgar-Turcsanyi M, Guttmann CR, Bakshi R, Weiner HL, Chitnis T. J Neurol Neurosurg Psychiatry. 2022 Aug 11;. doi: 10.1136/jnnp-2022-329353. [Epub ahead of print]. PMID: 35953266; not federally funded.
  20. Comparison of dimethyl fumarate and interferon outcomes in an MS cohort. Sattarnezhad N, Healy BC, Baharnoori M, Diaz-Cruz C, Stankiewicz J, Weiner HL, Chitnis T. BMC Neurol. 2022 Jul 11;22(1):252. doi: 10.1186/s12883-022-02761-8.  PMID: 35820822; Central PMCID: PMC9277810.
  21. Estimating the Association Between Physical Activity and Health-Related Quality of Life in Individuals with Multiple Sclerosis. Healy BC, Casady EC, Chitnis T, Weiner HL, Glanz BI. Mult Scler Relat Disord. 2022 Jul 2;92(1):87-96. Epub ahead of print.
  22. Early Predictors of Clinical and MRI Outcomes Using Least Absolute Shrinkage and Selection Operator (LASSO) in Multiple Sclerosis. Bose G, Healy BC, Lokhande HA, Sotiropoulos MG, Polgar-Turcsanyi M, Anderson M, Glanz BI, Guttman CRG, Bakshi R, Weiner HL, Chitnis T. Ann Neurol. 2022 Jul;92(1):87-96. doi: 10.1002/ana.26370. Epub 2022 May 4. PMID: 35429009.
  23. Disease modifying therapy management of multiple sclerosis after stem cell therapies: A retrospective case series. Manzano GS, Holroyd KB, Kaplan T, Bhattacharyya S, Chitnis T, Hotan G, Zurawski J, Galetta KM, Mateen FJ. Mult Scler Relat Disord. 2022 Jul;63:103861. doi: 10.1016/j.msard.2022.103861. Epub 2022 May 10. PMID: 35576727; not federally funded.
  24. COVID-19 severity is associated with worsened neurological outcomes in multiple sclerosis and related disorders. Conway SE, Healy BC, Zurawski J, Severson C, Kaplan T, Stazzone L, Galetta K, Chitnis T, Houtchens MK. Mult Scler Relat Disord. 2022 Jul;63:103946. doi: 10.1016/j.msard.2022.103946. Epub 2022 Jun 6. PMID: 35709663; not federally funded.
  25. Dissection of multiple sclerosis genetics identifies B and CD4+ T cells as driver cell subsets. Guo MH, Sama P, LaBarre BA, Lokhande H, Balibalos J, Chu C, Du X, Kheradpour P, Kim CC, Oniskey T, Snyder T, Soghoian DZ, Weiner HL, Chitnis T, Patsopoulos NA. Genome Biol. 2022 Jun 7;23(1):127. doi: 10.1186/s13059-022-02694-y. PMID: 35672799; PMCID: PMC9175345.
  26. Challenges to Longitudinal Characterization of Lower Urinary Tract Dysfunction in Multiple Sclerosis. Kaplan TB, Gopal A, Block VJ, Suskind AM, Zhao C, Polgar-Turcsanyi M, Saraceno TJ, Gomez R, Santaniello A, Consortium S, Ayoubi NE, Cree BAC, Hauser SL, Weiner H, Chitnis T, Khoury S, Bove R. Mult Scler Relat Disord. 2022 Jun;62:103793. doi: 10.1016/j.msard.2022.103793. Epub 2022 Apr 11. PMID: 35461057; not federally funded.
  27. Anti-CGRP therapies for migraine in multiple sclerosis patients. Gonzalez-Martinez A, Bose G, Chitnis T. Mult Scler. 2022 May 14;:13524585221096353. doi: 10.1177/13524585221096353. [Epub ahead of print] PMID: 35575242; not federally funded.
  28. MicroRNA-92a promotes CNS autoimmunity by modulating the regulatory and inflammatory T cell balance. Fujiwara M, Raheja R, Garo LP, Ajay AK, Kadowaki-Saga R, Karandikar SH, Gabriely G, Krishnan R, Beynon V, Paul A, Patel A, Saxena S, Hu D, Healy BC, Chitnis T, Gandhi R, Weiner HL, Murugaiyan G. J Clin Invest. 2022 May 16;132(10). doi: 10.1172/JCI155693. PMID: 35298438; PMCID: PMC9106347.
  29. Generating real-world data from health records: design of a patient-centric study in multiple sclerosis using a commercial health records platform. Hanson G, Chitnis T, Williams MJ, Gan RW, Julian L, Mace K, Chia J, Wormser D, Martinec M, Astorino T, Leviner N, Maung P, Jan A, Belendiuk K. JAMIA Open. 2022 Apr;5(1):ooab110. doi: 10.1093/jamiaopen/ooab110. eCollection 2022 Apr. PMID: 35155999; PMCID: PMC8827034.
  30. Cortical and Subcortical Dysmetabolism Are Dynamic Markers of Clinical Disability and Course in Anti-LGI1 Encephalitis. Rissanen E, Carter K, Cicero S, Ficke J, Kijewski M, Park MA, Kijewski J, Stern E, Chitnis T, Silbersweig D, Weiner HL, Kim CK, Lyons J, Klein JP, Bhattacharyya S, Singhal T. Neurol Neuroimmunol Neuroinflamm. 2022 Mar;9(2). doi: 10.1212/NXI.0000000000001136. Print 2022 Mar. PMID: 35091466; PMCID: PMC8802686.
  31. Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS. Lokhande H, Rosso M, Tauhid S, Chu R, Healy BC, Saxena S, Barro C, Paul A, Polgar-Turcsanyi M, Anderson M, Glanz BI, Kropshofer H, Granziera C, Leppert D, Kappos L, Kuhle J, Weiner HL, Bakshi R, Chitnis T. Mult Scler J Exp Transl Clin. 2022 Jan-Mar;8(1):20552173211069348. doi: 10.1177/20552173211069348. eCollection 2022 Jan-Mar. PMID: 35035990; PMCID: PMC8753083.
  32. Temporal trends of multiple sclerosis disease activity: Electronic health records indicators. Liang L, Kim N, Hou J, Cai T, Dahal K, Lin C, Finan S, Savovoa G, Rosso M, Polgar-Tucsanyi M, Weiner H, Chitnis T, Cai T, Xia Z. Mult Scler Relat Disord. 2022 Jan;57:103333. doi: 10.1016/j.msard.2021.103333. Epub 2021 Oct 24. PMID: 35158446; PMCID: PMC8849591.
  33. Patient-reported outcomes associated with transition to secondary progressive multiple sclerosis. Healy BC, Zurawski J, Chitnis T, Weiner HL, Glanz BI. Qual Life Res. 2021 Nov 16;. doi: 10.1007/s11136-021-03034-6. Epub 2021 Nov 16. PMID: 34783972.
  34. Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis. Hou J, Kim N, Cai T, Dahal K, Weiner H, Chitnis T, Cai T, Xia Z. JAMA Netw Open. 2021 Nov 1;4(11):e2134627. doi: 10.1001/jamanetworkopen.2021.34627. PMID: 34783826; PMCID: PMC8596196.
  35. Altered adipokine levels are associated with dimethyl fumarate treatment in multiple sclerosis patients. Baharnoori M, Wilson R, Saxena S, Gonzalez CT, Sotiropoulos MG, Keyhanian K, Healy BC, Chitnis T.Mult Scler Relat Disord. 2021 Oct 4;56:103311. doi: 10.1016/j.msard.2021.103311. Epub ahead of print. PMID: 34655958.
  36. Validation of Two Kinetic Assays for the Quantification of Endotoxin in Human Serum.
    Barro C, Paul A, Saleh F, Chitnis T, Weiner HL. Front Neurol. 2021 Jun 25;12:691683. doi: 10.3389/fneur.2021.691683. PMID: 34248828; PMCID: PMC8266997.
  37. Obesity is associated with the Optic Neuritis severity in Male patients with Multiple Sclerosis.
    Chu DT, Rosso M, Gonzalez CT, Saxena S, Healy BC, Weiner HL, Chitnis T. Mult Scler Relat Disord. 2021 Jun;51:102910. doi: 10.1016/j.msard.2021.102910. Epub 2021 Mar 21. PMID: 33799288.
  38. Gut Microbiome in Progressive Multiple Sclerosis.
    Cox LM, Maghzi AH, Liu S, Tankou SK, Dhang FH, Willocq V, Song A, Wasén C, Tauhid S, Chu R, Anderson MC, De Jager PL, Polgar-Turcsanyi M, Healy BC, Glanz BI, Bakshi R, Chitnis T, Weiner HL. Ann Neurol. 2021 Jun;89(6):1195-1211. doi: 10.1002/ana.26084. Epub 2021 Apr 30. PMID: 33876477; PMCID: PMC8132291.
  39. Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability.
    Sotiropoulos MG, Lokhande H, Healy BC, Polgar-Turcsanyi M, Glanz BI, Bakshi R, Weiner HL, Chitnis T. Mult Scler J Exp Transl Clin. 2021 May 28;7(2):20552173211015503. doi: 10.1177/20552173211015503. PMID: 34104471; PMCID: PMC8165535.
  40. An At-home Positive Psychology Intervention for Individuals with Multiple Sclerosis: A Phase 1 Randomized Controlled Trial.
    Freedman ME, Healy BC, Huffman JC, Chitnis T, Weiner HL, Glanz BI.  Int J MS Care. 2021 May-Jun;23(3):128-134. doi: 10.7224/1537-2073.2020-020. Epub 2020 Aug 31. PMID: 34177385; PMCID: PMC8218588.
  41. The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis.
    Glanz BI, Zurawski J, Casady EC, Shamah R, Weiner M, Chitnis T, Weiner HL, Healy BC. Mult Scler J Exp Transl Clin. 2021 Apr-Jun;7(2):20552173211007523. doi: 10.1177/20552173211007523. eCollection 2021 Apr-Jun. PMID: 34046184; PMCID: PMC8138295.
  42. Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis.
    Healy BC, Barker L, Bakshi R, Benedict RHB, Gonzalez CT, Chitnis T, Weiner HL, Glanz BI. Mult Scler. 2021 Apr;27(4):593-602. doi: 10.1177/1352458520913439. Epub 2020 Mar 31. PMID: 32228283.
  43. MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis.
    Rosso M, Healy BC, Saxena S, Paul A, Bjornevik K, Kuhle J, Benkert P, Leppert D, Guttmann C, Bakshi R, Weiner HL, Chitnis T. J Neuroimaging. 2021 Jan 21. doi: 10.1111/jon.12826. Epub ahead of print. PMID: 33476489.
  44. Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis.
    Moreira Ferreira VF, Caefer D, Erlich-Malona N, Healy BC, Chitnis T, Stankiewicz JM.  Mult Scler Int. 2020 Dec 17;2020:5471987. doi: 10.1155/2020/5471987. PMID: 33381316; PMCID: PMC7759400.
  45. Blood neurofilament light: a critical review of its application to neurologic disease.
    Barro C, Chitnis T, Weiner HL. Ann Clin Transl Neurol. 2020 Nov 4. doi: 10.1002/acn3.51234. Epub ahead of print. PMID: 33146954.
  46. Microstructural fronto-striatal and temporo-insular alterations are associated with fatigue in patients with multiple sclerosis independent of white matter lesion load and depression.
    Palotai M, Cavallari M, Koubiyr I, Morales Pinzon A, Nazeri A, Healy BC, Glanz B, Weiner HL, Chitnis T, Guttmann CR. Mult Scler. 2020 Nov;26(13):1708-1718. doi: 10.1177/1352458519869185. Epub 2019 Aug 16. PMID: 31418637.
  47. Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study.
    Zhao Y, Wang T, Bove R, Cree B, Henry R, Lokhande H, Polgar-Turcsanyi M, Anderson M, Bakshi R, Weiner HL, Chitnis T; SUMMIT Investigators. NPJ Digit Med. 2020 Oct 16;3:135. doi: 10.1038/s41746-020-00338-8. PMID: 33083570; PMCID: PMC7567781.
  48. COVID-19 in teriflunomide-treated patients with multiple sclerosis.
    Maghzi AH, Houtchens MK, Preziosa P, Ionete C, Beretich BD, Stankiewicz JM, Tauhid S, Cabot A, Berriosmorales I, Schwartz THW, Sloane JA, Freedman MS, Filippi M, Weiner HL, Bakshi R. J Neurol. 2020 Oct;267(10):2790-2796. doi: 10.1007/s00415-020-09944-8. Epub 2020 Jun 3. PMID: 32494856; PMCID: PMC7268971.
  49. Effect of assisted reproductive technology on multiple sclerosis relapses: Case series and meta-analysis.
    Bove R, Rankin K, Lin C, Zhao C, Correale J, Hellwig K, Michel L, Laplaud DA, Chitnis T. Mult Scler. 2020 Oct;26(11):1410-1419. doi: 10.1177/1352458519865118. Epub 2019 Aug 1. PMID: 31368394.
  50. Social support in multiple sclerosis: Associations with quality of life, depression, and anxiety.
    Ratajska A, Glanz BI, Chitnis T, Weiner HL, Healy BC. J Psychosom Res. 2020 Sep 16; 138:110252. PMID: 32971435.
  51. MRI activity in MS and completed pregnancy: Data from a tertiary academic center.
    Houtchens M, Bove R, Healy B, Houtchens S, Kaplan TB, Mahlanza T, Chitnis T, Bakshi R. Neurol Neuroimmunol Neuroinflamm. 2020 Sep 11;7(6):e890. doi: 10.1212/NXI.0000000000000890. PMID: 32917773; PMCID: PMC7643615.
  52. Improved relapse recovery in paediatric compared to adult multiple sclerosis.
    Chitnis T, Aaen G, Belman A, Benson L, Gorman M, Goyal MS, Graves JS, Harris Y, Krupp L, Lotze T, Mar S, Ness J, Rensel M, Schreiner T, Tillema JM, Waubant E, Weinstock-Guttman B, Roalstad S, Rose J, Weiner HL, Casper TC, Rodriguez M. Brain. 2020 Sep 1;143(9):2733-2741. doi: 10.1093/brain/awaa199. PMID: 32810215.
  53. Regional microglial activation in the substantia nigra is linked with fatigue in MS.
    Singhal T, Cicero S, Pan H, Carter K, Dubey S, Chu R, Glanz B, Hurwitz S, Tauhid S, Park MA, Kijewski M, Stern E, Bakshi R, Silbersweig D, Weiner HL. Neurol Neuroimmunol Neuroinflamm. 2020 Aug 7;7(5):e854. doi: 10.1212/NXI.0000000000000854. PMID: 32769103; PMCID: PMC7643614.
  54. Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity.
    Zhang T, Goodman M, Zhu F, Healy B, Carruthers R, Chitnis T, Weiner H, Cai T, De Jager P, Tremlett H, Xia Z. Neurol Neuroimmunol Neuroinflamm. 2020 Aug 19;7(6):e864. doi: 10.1212/NXI.0000000000000864. PMID: 32817202.
  55. Serum antibodies to phosphatidylcholine in MS.
    Sádaba MC, Rothhammer V, Muñoz Ú, Sebal C, Escudero E, Kivisäkk P, Garcia Sanchez MI, Izquierdo G, Hauser SL, Baranzini SE, Oksenberg JR, Álvarez-Lafuente R, Bakshi R, Weiner HL, Quintana FJ. Neurol Neuroimmunol Neuroinflamm. 2020 Jun 9;7(4):e765. doi: 10.1212/NXI.0000000000000765. PMID: 32518205; PMCID: PMC7309529.
  56. Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis.
    Rosso M, Gonzalez CT, Healy BC, Saxena S, Paul A, Bjornevik K, Kuhle J, Benkert P, Leppert D, Guttmann C, Bakshi R, Weiner HL, Chitnis T. Ann Clin Transl Neurol. 2020 Jun;7(6):945-955. doi: 10.1002/acn3.51060. Epub 2020 May 25. PMID: 32452160; PMCID: PMC7318095.
  57. Comparison of health-related quality of life across treatment groups in individuals with multiple sclerosis.
    Glanz BI, Zurawski J, Gonzalez CT, Shamah R, Ratajska A, Chitnis T, Weiner HL, Healy BC.  Mult Scler Relat Disord. 2020 May;40:101944. doi: 10.1016/j.msard.2020.101944. Epub 2020 Jan 11. PMID: 32007653.
  58. Clinical Advances in Sex- and Gender-Informed Medicine to Improve the Health of All: A Review.
    Bartz D, Chitnis T, Kaiser UB, Rich-Edwards JW, Rexrode KM, Pennell PB, Goldstein JM, O’Neal MA, LeBoff M, Behn M, Seely EW, Joffe H, Manson JE. JAMA Intern Med. 2020 Apr 1;180(4):574-583. doi:10.1001/jamainternmed.2019.7194. PMID: 32040165.
  59. A roadmap to precision medicine for multiple sclerosis.
    Chitnis T, Prat A. Mult Scler. 2020 Apr;26(5):522-532. doi: 10.1177/1352458519881558. Epub 2020 Jan 22. PMID: 31965904.
  60. Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis.
    Healy BC, Barker L, Bakshi R, Benedict RHB, Gonzalez CT, Chitnis T, Weiner HL, Glanz BI. Mult Scler. 2020 Mar 31:1352458520913439. doi: 10.1177/1352458520913439. Epub ahead of print. PMID: 32228283.
  61. Brain MRI Predicts Worsening Multiple Sclerosis Disability over 5 Years in the SUMMIT Study.
    Bakshi R, Healy BC, Dupuy SL, Kirkish G, Khalid F, Gundel T, Asteggiano C, Yousuf F, Alexander A, Hauser SL, Weiner HL, Henry RG; SUMMIT consortium. J Neuroimaging. 2020 Mar;30(2):212-218. doi: 10.1111/jon.12688. Epub 2020 Jan 29. PMID: 31994814; PMCID: PMC7194808.
  62. Prospective growth and developmental outcomes in infants born to mothers with multiple sclerosis.
    Mahlanza TD, Manieri MC, Klawiter EC, Solomon AJ, Lathi E, Ionete C, Berriosmorales I, Severson C, Stankiewicz J, Cabot A, Elkort M, Chitnis T, Bove R, Katz J, Houtchens M. Mult Scler. 2020 Feb 17:1352458520904545. doi: 10.1177/1352458520904545. Epub ahead of print. PMID: 32065561.
  63. Association Between Cigarette Smoking and Multiple Sclerosis: A Review.
    Rosso M, Chitnis T. JAMA Neurol. 2020 Feb 1;77(2):245-253. doi: 10.1001/jamaneurol.2019.4271. PMID: 31841592.
  64. 7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions.
    Zurawski J, Tauhid S, Chu R, Khalid F, Healy BC, Weiner HL, Bakshi R. Mult Scler. 2020 Feb;26(2):177-187. doi: 10.1177/1352458519885106. Epub 2019 Nov 12. PMID: 31714181.
  65. Serum NFL levels should be used to monitor multiple sclerosis evolution.
    – Commentary. Chitnis T. Mult Scler. 2020 Jan;26(1):21-22. doi: 10.1177/1352458519880471. Epub 2019 Oct 18. PMID: 31625830.
  66. Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis.
    Chitnis T, Glanz BI, Gonzalez C, Healy BC, Saraceno TJ, Sattarnezhad N,Diaz-Cruz C, Polgar-Turcsanyi M, Tummala S, Bakshi R, Bajaj VS, Ben-Shimol D, Bikhchandani N, Blocker AW, Burkart J, Cendrillon R, Cusack MP, Demiralp E, Jooste SK, Kharbouch A, Lee AA, Lehár J, Liu M, Mahadevan S, Murphy M, Norton LC, Parlikar TA, Pathak A, Shoeb A, Soderberg E, Stephens P, Stoertz AH, Thng F, Tumkur K, Wang H, Rhodes J, Rudick RA, Ransohoff RM, Phillips GA, Bruzik E, Marks WJ, Weiner HL, Snyder TM. NPJ Digit Med. 2019 Dec 11;2:123. doi: 10.1038/s41746-019-0197-7. eCollection 2019. PMID: 31840094; PMCID: PMC6906296.
  67. Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis.
    Healy BC, Zurawski J, Gonzalez CT, Chitnis T, Weiner HL, Glanz BI. Mult Scler. 2019 Nov;25(13):1791-1799. doi: 10.1177/1352458518810159. Epub 2018 Nov 1. PMID: 30381985.
  68. History of fatigue in multiple sclerosis is associated with grey matter atrophy.
    Palotai M, Nazeri A, Cavallari M, Healy BC, Glanz B, Gold SM, Weiner HL, Chitnis T, Guttmann CRG. Sci Rep. 2019 Oct 14;9(1):14781. doi:10.1038/s41598-019-51110-2. PMID: 31611598; PMCID: PMC6791855.
  69. γδ T Cell-Secreted XCL1 Mediates Anti-CD3-Induced Oral Tolerance.
    Rezende RM, Nakagaki BN, Moreira TG, Lopes JR, Kuhn C, Tatematsu BK, Boulenouar S, Maghzi AH, Rubino S, Menezes GB, Chitnis T, Weiner HL. J Immunol. 2019 Nov 15;203(10):2621-2629. doi: 10.4049/jimmunol.1900784. Epub 2019 Oct 2. PMID:31578268; PMCID: PMC6832869.
  70. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
    Yano H, Gonzalez C, Healy BC, Glanz BI, Weiner HL, Chitnis T. Mult Scler Relat Disord. 2019 Oct;35:119-127. doi: 10.1016/j.msard.2019.07.021. Epub 2019 Jul 25. PMID: 31374460.
  71. The impact of cervical spinal cord atrophy on quality of life in multiple sclerosis.
    Zurawski J, Glanz BI, Healy BC, Tauhid S, Khalid F, Chitnis T, Weiner HL, Bakshi R. J Neurol Sci. 2019 Aug 15;403:38-43. doi: 10.1016/j.jns.2019.04.023. Epub 2019 Apr 18. PMID: 31207364.
  72. A Pilot Study to Assess At-Home Speed of Processing Training for Individuals with Multiple Sclerosis.
    Barker L, Healy BC, Chan E, Leclaire K, Glanz BI.  Mult Scler Int. 2019 Jun 3;2019:3584259. doi: 10.1155/2019/3584259. eCollection 2019. PMID: 31275652; PMCID: PMC6582794.
  73. Multiple sclerosis and sarcoidosis: A case for coexistence.
    Tyshkov C, Pawate S, Bradshaw MJ, Kimbrough DJ, Chitnis T, Gelfand JM, Ryerson LZ, Kister I. Neurol Clin Pract. 2019 Jun;9(3):218-227. doi: 10.1212/CPJ.0000000000000629. PMID: 31341709; PMCID: PMC6615652.
  74. Food allergies are associated with increased disease activity in multiple sclerosis.
    Fakih R, Diaz-Cruz C, Chua AS, Gonzalez C, Healy BC, Sattarnezhad N, Glanz BI, Weiner HL, Chitnis T. J Neurol Neurosurg Psychiatry. 2019 Jun;90(6):629-635. doi: 10.1136/jnnp-2018-319301. Epub 2018 Dec 18. PMID: 30563943.
  75. Computerized Cognitive Behavioral Therapy for Treatment of Depression in Multiple Sclerosis: A Narrative Review of Current Findings and Future Directions.
    Ratajska A, Zurawski J, Healy B, Glanz BI. Int J MS Care. 2019 May-Jun;21(3):113-123. doi: 10.7224/1537-2073.2017-094. PMID: 31191176; PMCID: PMC6552991.
  76. Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study.
    Zivadinov R, Medin J, Khan N, Korn JR, Chitnis T, Naismith RT, Alvarez E, Dwyer MG, Bergsland N, Carl E, Silva D, Weinstock-Guttman B; MS-MRIUS Study Group. Mult Scler Relat Disord. 2019 Jan;27:65-73. doi: 10.1016/j.msard.2018.09.037. Epub 2018 Oct 3. PMID: 30342416.
  77. Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis.
    Desai RJ, Mahesri M, Gagne JJ, Hurley E, Tong A, Chitnis T, Minden S, Spettell CM, Matlin OS, Shrank WH, Choudhry NK. J Manag Care Spec Pharm. 2019 Jan;25(1):113-121. PMID: 30589630.
  78. Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patients.
    Fakih R, Matiello M, Chitnis T, Stankiewicz JM. J Neurol. 2018 Nov;265(11):2688-2694. PMID: 30203314.
  79. Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis.
    Chitnis T, Gonzalez C, Healy BC, Saxena S, Rosso M, Barro C, Michalak Z, Paul A, Kivisakk P, Diaz-Cruz C, Sattarnezhad N, Pierre IV, Glanz BI, Tomic D, Kropshofer H, Häring D, Leppert D, Kappos L, Bakshi R, Weiner HL, Kuhle J. Ann Clin Transl Neurol. 2018 Oct 16;5(12):1478-1491. eCollection 2018. PMID: 30564615; PMCID: PMC6292183.
  80. SUMMIT Consortium. SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.
    Bove R, Chitnis T, Cree BA, Tintoré M, Naegelin Y, Uitdehaag BM, Kappos L, Khoury SJ, Montalban X, Hauser SL, Weiner HL; Mult Scler. 2018 Oct;24(11):1485-1498. PMID: 28847219; PMCID: PMC5821573.
  81. Quantitative MRI analysis of cerebral lesions and atrophy in post-partum patients with multiple sclerosis.
    Khalid F, Healy BC, Dupuy SL, Chu R, Chitnis T, Bakshi R, Houtchens M. J Neurol Sci. 2018 Sep 15;392:94-99. PMID: 30031994.
  82. Identification of MS-specific serum miRNAs in an international multicenter study.
    Regev K, Healy BC, Paul A, Diaz-Cruz C, Mazzola MA, Raheja R, Glanz BI, Kivisäkk P, Chitnis T, Jagodic M, Piehl F, Olsson T, Khademi M, Hauser S, Oksenberg J, Khoury SJ, Weiner HL, Gandhi R. Neurol Neuroimmunol Neuroinflamm. 2018 Aug 20;5(5):e491. eCollection 2018. PMID: 30175165; PMCID: PMC6117192.
  83. Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis.
    Raheja R, Regev K, Healy BC, Mazzola MA, Beynon V, Von Glehn F, Paul A,Diaz-Cruz C, Gholipour T, Glanz BI, Kivisakk P, Chitnis T, Weiner HL, Berry JD,Gandhi R. Muscle Nerve. 2018 Aug;58(2):261-269. PMID: 29466830; PMCID: PMC6103911.
  84. Agreement analysis comparing iPad LCVA and Sloan testing in multiple sclerosis patients.
    Sattarnezhad N, Farrow S, Kimbrough D, Glanz B, Healy B, Chitnis T. Agreement analysis comparing iPad LCVA and Sloan testing in multiple sclerosis patients. Mult Scler. 2018 Jul;24(8):1126-1130. doi: 10.1177/1352458517713667. Epub 2017 Jun 6. PMID: 28585909.
  85. Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remittin multiple sclerosis.
    Dastagir A, Healy BC, Chua AS, Chitnis T, Weiner HL, Bakshi R, Tauhid S. eNeurologicalSci. 2018 Jul 4;12:42-46. eCollection 2018. PMID: 30229136; PMCID: PMC6141305.
  86. Fingolimod’s Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS.
    Zivadinov R, Medin J, Khan N, Korn JR, Bergsland N, Dwyer MG, Chitnis T, Naismith RT, Alvarez E, Kinkel P, Cohan S, Hunter SF, Silva D, Weinstock-Guttman B; MS-MRIUS investigators. J Neuroimaging. 2018 Jul;28(4):399-405. PMID:29749661.
  87. Short Report: A Pilot Study of a Group Positive Psychology Intervention for Patients with Multiple Sclerosis.
    Leclaire K, Cecil A, LaRussa A, Stuart F, Hemond CC, Healy BC, Chitnis T, Weiner H, Huffman J, Glanz BI. Int J MS Care. 2018 May-Jun;20(3):136-141. PMID: 29896050; PMCID: PMC5991506.
  88. Evaluating the Association between Enlarged Perivascular Spaces and Disease Worsening in Multiple Sclerosis.
    Cavallari M, Egorova S, Healy BC, Palotai M, Prieto JC, Polgar-Turcsanyi M, Tauhid S, Anderson M, Glanz B, Chitnis T, Guttmann CRG. J Neuroimaging. 2018 May;28(3):273-277. PMID: 29226505.
  89. Complexity of MS management in the current treatment era. Neurology.
    Chitnis T, Giovannoni G, Trojano M. 2018 Apr 24;90(17):761-762. PMID: 29686111.
  90. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
    Baharnoori M, Gonzalez CT, Chua A, Diaz-Cruz C, Healy BC, Stankiewicz J, Weiner HL, Chitnis T. Mult Scler Relat Disord. 2018 Feb;20:51-57. PMID:29304497.
  91. Oral contraceptives and MS disease activity in a contemporary real-world cohort.
    Bove R, Rankin K, Chua AS, Saraceno T, Sattarnezhad N, Greeke E, Stuart F, LaRussa A, Glanz BI, Chitnis T. Mult Scler. 2018 Feb;24(2):227-230. PMID: 28155573.
  92. Fatty acid binding protein-4 is associated with disability in multiple sclerosis patients.
    Bove R, Healy BC, Musallam A, Soltany P, Diaz-Cruz C, Sattarnezhad N, Glanz BI, Kivisäkk P, Miller KK, Chitnis T. Mult Scler. 2018 Jan 1:1352458517750768. PMID: 29320952; PMCID: PMC6026579.
  93. The role of testosterone in MS risk and course.
    Chitnis T. Mult Scler. 2018 Jan;24(1):36-41. PMID: 29307293.
  94. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
    Yousuf F, Dupuy SL, Tauhid S, Chu R, Kim G, Tummala S, Khalid F, Weiner HL, Chitnis T, Healy BC, Bakshi R. J Neurol Sci. 2017 Dec 15;383:221-229. PMID: 29146095.
  95. Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis.
    Eagle T, Stuart F, Chua AS, LaRussa A, Leclaire K, Cook SL, Chitnis T, Weiner HL, Glanz BI, Healy BC. Mult Scler Relat Disord. 2017 Nov;18:196-201. PMID: 29141809.
  96. Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis.
    Kim G, Chu R, Yousuf F, Tauhid S, Stazzone L, Houtchens MK, Stankiewicz JM, Severson C, Kimbrough D, Quintana F, Chitnis T, Weiner HL, Healy BC, Bakshi R. Int J Neurosci. 2017 Nov;127(11):971-980. PMID: 28100092.
  97. The effect of alcohol and red wine consumption on clinical and MRI outcomes in multiple sclerosis.
    Diaz-Cruz C, Chua AS, Malik MT, Kaplan T, Glanz BI, Egorova S, Guttmann CRG, Bakshi R, Weiner HL, Healy BC, Chitnis T. Mult Scler Relat Disord. 2017 Oct;17:47-53. PubMed PMID: 29055473.
  98. Depression and fatigue in patients with multiple sclerosis.
    Greeke EE, Chua AS, Healy BC, Rintell DJ, Chitnis T, Glanz BI. J Neurol Sci. 2017 Sep 15;380:236-241. PMID:28870578.
  99. Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis.
    Healy BC, Buckle GJ, Ali EN, Egorova S, Khalid F, Tauhid S, Glanz BI, Chitnis T, Guttmann CRG, Weiner HL, Bakshi R.. J Neuroimaging. 2017 Sep;27(5):481-485. PMID: 28261936; PMCID: PMC5600109.
  100. Wearable biosensors to monitor disability in multiple sclerosis.
    Bradshaw MJ, Farrow S, Motl RW, Chitnis T. Neurol Clin Pract. 2017 Aug;7(4):354-362. PMID: 29185551; PMCID: PMC5648206.
  101. Joint assessment of dependent discrete disease state processes.
    Engler D, Chitnis T, Healy BC. Stat Methods Med Res. 2017 Jun;26(3):1182-1198. PMID: 25698716.
  102. Spinal Cord as an Adjunct to Brain Magnetic Resonance Imaging in Defining "No Evidence of Disease Activity" in Multiple Sclerosis.
    Tummala S, Singhal T, Oommen VV, Kim G, Khalid F, Healy BC, Bakshi R. Int J MS Care. 2017 May-Jun;19(3):158-164. PMID: 28603465; PMCID: PMC5460870.
  103. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
    Int J Neurosci. Khalid F, Tauhid S, Chua AS, Healy BC, Stankiewicz JM, Weiner HL, Bakshi R. 2017 May;127(5):396-403. PMID: 27143245.
  104. Exploration of machine learning techniques in predicting multiple sclerosis disease course.
    Zhao Y, Healy BC, Rotstein D, Guttmann CR, Bakshi R, Weiner HL, Brodley CE, Chitnis T. PLoS One. 2017 Apr 5;12(4):e0174866. eCollection 2017. PMID:28379999; PMCID: PMC5381810.
  105. Association between serum microRNAs and magnetic resonance imaging measures of multiple sclerosis severity.
    Regev K, Healy BC, KhalidF, Paul A, Chu R, Tauhid S, Tummala S, Diaz-Cruz C, Raheja R, Mazzola MA, von Glehn F, Kivisakk P, Dupuy SL, Kim G, Chitnis T, Weiner HL, Gandhi R, Bakshi R. JAMA Neurol. 2017 Mar 1;74(3):275-85. PMID: 28114622; PMCID: PMC6014611.
  106. The Effect of Glatiramer Acetate on Spinal Cord Volume in Relapsing-Remitting Multiple Sclerosis.
    Singhal T, Tauhid, S, Hurwitz S, Neema M, Bakshi R. J Neuroimaging. 2017 Jan;27(1):33-6. PMID: 27466943; PMCID: PMC5248648.
  107. The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis.
    Dupuy SL, Tauhid S, Hurwitz S, Chu R, Yousuf F, Bakshi R. Neurol Ther. 2016 Dec;5(2):215-29. PMID 27744504; PMCID: PMC5130921.
  108. Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients.
    Cavallari M, Palotai M, Glanz BI, Egorova S, Prieto JC, Healy BC, Chitnis T, Guttmann CR. Mult Scler. 2016 Dec;22(14):1841-1849. PMID: 26920374.
  109. The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis.
    Dupuy SL, Khalid F, Healy BC, Bakshi S, Neema M, Tauhid S, Bakshi R. BMC Med Imaging. 2016 Oct 5;16(1):56. PMID: 27716096; PMCID: PMC5053209.
  110. Experience with long-term rituximab use in a multiple sclerosis clinic.
    Barra ME, Soni D, Vo KH, Chitnis T, Stankiewicz JM.  Mult Scler J Exp Transl Clin. 2016 Oct 9;2:2055217316672100. PMID: 28607739; PMCID: PMC5433395.
  111. Risk attitudes and risk perceptions in individuals with multiple sclerosis.
    Glanz BI, Greeke E, LaRussa A, Stuart F, Rintell DJ, Chitnis T, Healy BC. Mult Scler J Exp Transl Clin. 2016 Sep 2;2:2055217316665406. doi: 10.1177/2055217316665406. PMID: 28607735; PMCID: PMC5453630.
  112. Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis.
    Regev K, Paul A, Healy B, von Glenn F, Diaz-Cruz C, Gholipour T, Mazzola MA, Raheja R, Nejad P, Glanz BI, Kivisakk P, Chitnis T, Weiner HL, Gandhi R. Neurol Neuroimmunol Neuroinflamm. 2016 Aug 23;3(5):e267. eCollection 2016. PMID: 27606352; PMCID: PMC4996540.
  113. Complex relation of HLA-DRB1*1501, age at menarche, and age at multiple sclerosis onset.
    Bove R, Chua AS, Xia Z, Chibnik L, De Jager PL, Chitnis T.  Neurol Genet. 2016 Jul 26;2(4):e88. eCollection 2016. PMID: 27504495; PMCID: PMC4962522.
  114. Longitudinal BMI trajectories in multiple sclerosis: Sex differences in association with disease severity.
    Bove R, Musallam A, Xia Z, Baruch N, Messina S, Healy BC, Chitnis T.  Mult Scler Relat Disord. 2016 Jul;8:136-40. PMID: 27456889.
  115. The Contribution of Cortical Lesions to a Composite MRI Scale of Disease Severity in Multiple Sclerosis.
    Yousuf F, Kim G, Tauhid S, Glanz BI, Chu R, Tummala S, Healy BC, Bakshi R.  Front Neurol. 2016 Jun 29;7:99. eCollection 2016. PMID: 27445966; PMCID: PMC4925661.
  116. Alterations of the human gut microbiome in multiple sclerosis.
    Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, Patel B, Mazzola MA, Liu S, Glanz BL, Cook S, Tankou S, Stuart F, Melo K, Nejad P, Smith K, Topçuolu BD, Holden J, Kivisäkk P, Chitnis T, De Jager PL, Quintana FJ, Gerber GK, Bry L, Weiner HL. Nat Commun. 2016 Jun 28;7:12015. PMID: 27352007; PMCID: PMC4931233.
  117. Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort.
    Bove R, Healy BC, Musallam A, Glanz BI, De Jager PL, Chitnis T. Mult Scler. 2016 June;22(7):935-43. PMID: 26447063; PMCID: PMC4824677.
  118. The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis.
    Oommen VV, Tauhid S, Healy BC, Chua AS, Malik MT, Diaz-Cruz C, Dupuy SL, Weiner HL, Chitnis T, Bakshi R. J Neuroimaging. 2016 Mar;26(2):184-7. PMID: 26445919; PMCID: PMC5057343.
  119. Cognitive and patient-reported outcomes in adults with pediatric multiple sclerosis.Baruch NF, O'Donnell EH, Glanz BI, Benedict RH, Musallam AJ, Healy BC, Rintell D, Chitnis T. Mult Scler. 2016 Mar;22(3):354-61. PMID: 26041802.
  120. An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis.
    Kim G, Tauhid S, Dupuy SL, Tummala S, Khalid F, Healy BC, Bakshi R. J Neurol. 2016 Mar;263(3):531-8. PMID: 26754005; PMCID: PMC4785194.
  121. Genes and Environment in Multiple Sclerosis project: A platform to investigate multiple sclerosis risk.
    Xia Z, White CC, Owen EK, Von Korff A, Clarkson SR, McCabe CA, Cimpean M, Winn PA, Hoesing A, Steele SU, Cortese IC, Chitnis T, Weiner HL, Reich DS, Chibnik LB, De Jager PL. Ann Neurol. 2016 Feb;79(2):178-89. PMID: 26583565; PMCID: PMC4778957.
  122. Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosis.
    Bakshi R, Yeste A, Patel B, Tauhid S, Tummala S, Rahbari R, Chu R, Regev K, Kivisakk P, Weiner HL, Quintana FJ. Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(2):e200. eCollection 2016. PMID: 26894202; PMCID: PMC4747479.
  123. Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation.
    Mazzola MA, Raheja R, Murugaiyan G, Rajabi H, Kumar D, Pertel T, Regev K, Griffin R, Aly L, Kivisakk P, Nejad P, Patel B, Gwanyalla N, Hei H, Glanz B, Chitnis T, Weiner HL, Gandhi R. J Neuroinflammation. 2015 Dec 30;12:245. PMID: 26714756; PMCID: PMC4696082.
  124. Patient-reported outcomes in multiple sclerosis: Relationships among existing scales and the development of a brief measure.
    Chua AS, Glanz BI, Guarino AJ, Cook SL, Greeke EE, Little GE, Chitnis T, Healy BC.  Mult Scler Relat Disord. 2015 Nov;4(6):598-606. PMID: 26590669.
  125. Brain MRI leasions and atrophy are associated with employment status in patient multiple sclerosis.
    Tauhid S, Chu R, Sasane R, Glanz BI, Neema M, Miller JR, Kim G, Signorovitch JE, Healy BC, Chitnis T, Weiner HL, Bakshi R. J Neurol. 2015 Nov;262(11):2425-32. PMID: 26205635; PMCID: PMC4639581.
  126. Removing confounding factors via constraint-based clustering: An application to finding homogeneous groups of multiple sclerosis patients.
    Liu J, Brodley CE, Healy BC, Chitnis T. Artif Intell Med. 2015 Oct;65(2):79-88. PMID: 26253753.
  127. Effect of vitamin D on MS activity by disease-modifying therapy class.
    Rotstein DL, Healy BC, Malik MT, Carruthers RL, Musallam AJ, Kivisakk P, Weiner HL, Glanz BI, Chitnis T.  Neurol Neuroimmunol Neuroinflamm. 2015 Oct 29;2(6):e167. eCollection 2015. PMID: 26568968, PMCID: PMC4630683.
  128. The 2D:4D ratio, a proxy for prenatal androgen levels, differs in men with and without MS.
    Bove R, Malik MT, Diaz-Cruz C, Chua A, Saraceno TJ, Bargiela D, Greeke E, Glanz BI, Chitnis T. Neurology. 2015 Oct 6;85(14):1209-13. PMID: 26341868; PMCID: PMC4607599.
  129. Using multiple imputation to efficiently correct cerebral MRI whole brain lesion and atrophy data in patients with multiple sclerosis.
    Chua AS, Egorova S, Anderson MC, Polgar-Turcsanyi M, Chitnis T, Weiner HL, Guttmann CR, Bakshi R, Healy BC. Neuroimage. 2015 Oct1; 119:81-8. PMID: 26093330.
  130. Removing confounding factors via constraint-based clustering: An application to finding homogenous groups of multiple sclerosis patients.
    Liu J, Brodley CE, Healy BC, Chitnis T. Artif Intell Med. 2015 Oct;65(2):79-88. PMID: 26253753.
  131. T1- vs. T2-based MRI measures of spinal cord volume in healthy subjects and patients with multiple sclerosis.
    Kim G, Khalid F, Oommen VV, Tauhid S, Chu R, Horsfield MA, Healy BC, Bakshi R. BMC Neurol. 2015 Jul 31;15:124. PMID: 26227960; PMCID: PMC4521382.
  132. Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models.
    Chua AS, Egorova S, Anderson MC, Polgar-Turcsanyi M, Chitnis T, Weiner HL, Guttmann CR, Bakshi R, Healy BC. Neuroimage Clin. 2015 Jul 2;8:606-10. eCollection 2015. PMID: 26199872; PMCID: PMC4506959.
  133. A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity.
    Esposito F, Sorosina M, Ottoboni L, Lim ET, Replogle JM, Raj T, Brambilla P, Liberatore G, Guaschino C, Romeo M, Pertel T, Stankiewicz JM, Martinelli V, Rodegher M, Weiner HL, Brassat D, Benoist C, Patsopoulos NA, Comi G, Elyaman W, Martinelli Boneschi F, De Jager PL.  Ann Neurol. 2015 Jul;78(1):115-27. PMID: 25914168.
  134. Progression rates and sample size estimates for PPMS based on the CLIMB study population.
    Raghavan K, Healy BC,Carruthers RL, Chitnis T. Mult Slero. 2015 Feb;21(2):180-8. PMID: 25070676.
  135. Evaluation of no evidence disease activity in a 7-year old longitudinal multiple sclerosis cohort.
    Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL. JAMA Neurol. 2015 Feb;72(2):152-8. PMID: 25531931.
  136. Patients report worse MS symptoms after menopause: findings from an online cohort.
    Bove R, Healy BC, Secor E, Vaughan T, Katic B, Chitnis T, Wicks P, De Jager PL. Mult Scler Relat Disord. 2015 Jan;4(1):18-24. PMID: 25787049.
  137. Addressing Human Subjectivity via Transfer Learning: An Application to Predicting Disease Outcome in Multiple Sclerosis Patients.
    Zhao Y, Brodley CE, Chitnis T, Healy BC. Proceedings of the 2014 SIAM International Conference on Data Mining. p965-73, 2014.
  138. MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis.
    Tauhid S, Neema M, Healy BC, Weiner HL, Bakshi R. Journal of the Neurological Sciences. 2014 Nov 15;346(1-2):250-54. PMID: 25220114.
  139. An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2.
    Bakshi R, Neema M, Tauhid S, Healy BC, Glanz BI, Kim G, Miller J, Berkowitz JL, Bove R, Houtchens MK, Severson C, Stankiewicz JM, Stazzone L, Chitnis T, Guttmann CR, Weiner HL, Ceccarelli A. Neuroreport. 2014 Oct 1;25(14):1156-61. PMID: 25100554; PMCID: PMC4166046.
  140. Low testosterone is associated with disability in men with multiple sclerosis.
    Bove R, Musallam A, Healy B Raghavan K, Glanz B, Bakshi R, Weiner H, De Jager P, Miller K, Chitnis T. Mult Scler. 2014 Oct;20(12):1584-92. PMID: 24710799; PMCID: PMC4188801.
  141. An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy.
    Carruthers RL, Rotstein DL, Healy BC, Chitnis T, Weiner HL, Buckle GJ. Mult Scler. 2014 Sep;20(10):1381-90. PMID: 24852928.
  142. Treatment satisfaction in multple sclerosis.
    Glanz BI, Musallam A, Rintell DJ, Chitnis T, Weiner HL, Healy BC. Int Journal MS Care. 2014 Summer;16(2):68-75. PMID: 25061430; PMCID: PMC4106393.
  143. Menopause in multiple sclerosis: therapeutic considerations.
    Bove R, Chitnis T, Houtchens M. J Neurol. 2014 Jul;261(7):1257-68. Review. PMID: 24101131.
  144. Factors associated with recovery from acute optic neurtis in patiens with multiple sclerosis.
    Malik MT, Healy BC, Benson LA, Kivisäkk P, Musallam A, Weiner HL, Chitnis T. Neurology. 2014 Jun 17;82(24):2173-9. PMID: 24850491; PMCID: PMC:4113460.
  145. Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
    Carruthers RL, Chitnis T, Healy BC. Mult Scler. 2014 May;20(6):757-60. PMID: 24189572.
  146. Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development.
    Kivisäkk P, Healy BC, Francois K, Gandhi R, Gholipour T, Egorova S, Sevdalinova V, Quintana F, Chitnis T, Weiner HL, Khoury SJ. Mult Scler. 2014 Apr;20(4):438-44. PMID: 24005026.
  147. Elevated relapse rate in pediatric compared to adult MS persist for at least 6 years.
    Benson LA, Healy BC, Gorman MP, Baruch NF, Gholipour T, Musallam A, Chitnis T. Mult Sler  Relat Disord. 2014 Mar3(2):186-93. PMID: 25878006.
  148. Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus.
    Ottoboni L, Frohlich IY, Lee M, Healy BC, Keenan BT, Xia Z, Chitnis T, Guttmann CR, Khoury SJ, Weiner HL, Hafler DA, De Jager PL. Neurology. 2013 Nov 26;81(22):1891-9. PMID: 24174586; PMCID: PMC3843384.
  149. Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study.
    Chitnis T, Guttmann CR, Zaitsev A, Musallam A, Weinstock-Guttman B, Yeh A, Rodriguez M, Ness J, Gorman MP, Healy BC, Kuntz N, Chabas D, Strober JB, Waubant E, Krupp L, Pelletier D, Erickson B, Bergsland N, Zivadinov R; U.S. Network of Pediatric MS Centers of Excellence. BMC Neurol. 2013 Nov 13;13:173. PMID: 24225378; PMCID: PMC3832402.
  150. Modeling disease severity in multiple sclerosis using electronic health records.
    Xia Z, Secor E, Chibnik LB, Bove RM, Cheng S, Chitnis T, Cagan A, Gainer VS, Chen PJ, Liao KP, Shaw SY, Ananthakrishnan AN, Szolovits P, Weiner HL, Karlson EW, Murphy SN, Savova GK, Cai T, Churchill SE, Plenge RM, Kohane IS, De Jager PL. PLoS One. 2013 Nov 11;8(11):e78927. eCollection 2013. PMID: 24244385; PMCID: PMC3823928.
  151. Increased leptin and A-FABP levels in relapsing and progressive forms of MS.
    Messina S,Vargas-Lowy D, Musallam A, Healy BC, Kivisakk P, Gandhi R, Bove, R, Gholipou T, Khoury SJ, Weiner HL, Chitnis T. BMC Neurol. 2013 Nov 11;13:172. PMID: 2421502; PMCID: PMC3829106.
  152. Sexual disparities in the incidence and course of MS.
    Bove R, Chitnis T. Clin Immunol. 2013 Nov;149(2):201-10. Review. PMID: 23608496.
  153. Sex influences in autoimmune disease.
    Chitnis T, Khoury SJ. Clin Immunol. 2013 Nov;149(2):169. PMID: 24012474.
  154. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.
    International Multiple Sclerosis Genetics Consortium (IMSGC), Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, Shah TS, Spencer C, Booth D, Goris A, Oturai A, Saarela J, Fontaine B, Hemmer B, Martin C, Zipp F, D’Alfonso S, Martinelli-Boneschi F, Taylor B, Harbo HF, Kockum I, Hillert J, Olsson T, Ban M, Oksenberg JR, Hintzen R, Barcellos LF; Wellcome Trust Case Control Consortium 2 (WTCCC2); International IBD Genetics Consortium (IIBDGC), Agliardi C, Alfredsson L, Alizadeh M, Anderson C, Andrews R, Søndergaard HB, Baker A, Band G, Baranzini SE, Barizzone N, Barrett J, Bellenguez C, Bergamaschi  L, Bernardinelli L, Berthele A, Biberacher V, Binder TM, Blackburn H, Bomfim IL,  Brambilla P, Broadley S, Brochet B, Brundin L, Buck D, Butzkueven H, Caillier SJ, Camu W, Carpentier W, Cavalla P, Celius EG, Coman I, Comi G, Corrado L, Cosemans  L, Cournu-Rebeix I, Cree BA, Cusi D, Damotte V, Defer G, Delgado SR, Deloukas P,  di Sapio A, Dilthey AT, Donnelly P, Dubois B, Duddy M, Edkins S, Elovaara I, Esposito F, Evangelou N, Fiddes B, Field J, Franke A, Freeman C, Frohlich IY, Galimberti D, Gieger C, Gourraud PA, Graetz C, Graham A, Grummel V, Guaschino C, Hadjixenofontos A, Hakonarson H, Halfpenny C, Hall G, Hall P, Hamsten A, Harley J, Harrower T, Hawkins C, Hellenthal G, Hillier C, Hobart J, Hoshi M, Hunt SE, Jagodic M, Jelčić I, Jochim A, Kendall B, Kermode A, Kilpatrick T, Koivisto K, Konidari I, Korn T, Kronsbein H, Langford C, Larsson M, Lathrop M, Lebrun-Frenay  C, Lechner-Scott J, Lee MH, Leone MA, Leppä V, Liberatore G, Lie BA, Lill CM, Lindén M, Link J, Luessi F, Lycke J, Macciardi F, Männistö S, Manrique CP, Martin R, Martinelli V, Mason D, Mazibrada G, McCabe C, Mero IL, Mescheriakova J, Moutsianas L, Myhr KM, Nagels G, Nicholas R, Nilsson P, Piehl F, Pirinen M, Price SE, Quach H, Reunanen M, Robberecht W, Robertson NP, Rodegher M, Rog D, Salvetti  M, Schnetz-Boutaud NC, Sellebjerg F, Selter RC, Schaefer C, Shaunak S, Shen L, Shields S, Siffrin V, Slee M, Sorensen PS, Sorosina M, Sospedra M, Spurkland A, Strange A, Sundqvist E, Thijs V, Thorpe J, Ticca A, Tienari P, van Duijn C, Visser EM, Vucic S, Westerlind H, Wiley JS, Wilkins A, Wilson JF, Winkelmann J, Zajicek J, Zindler E, Haines JL, Pericak-Vance MA, Ivinson AJ, Stewart G, Hafler  D, Hauser SL, Compston A, McVean G, De Jager P, Sawcer SJ, McCauley JL. Nat Genet. 2013 Nov;45(11):1353-60. PMID: 24076602, PMCID: PMC3832895.
  155. No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50.
    Bove R, Musallam A, Healy BC, Houtchens M, Glanz BI, Khoury S, Guttmann CR, De Jager PL, Chitnis T. BMC Neurol. 2013 Jul 3;13:73. PMID: 23822612; PMCID: PMC3707791.
  156. Circulating MicroRNAs as biomarkers for disease staging in multiple sclerosis.
    Gandhi R, HealyB, Gholipour T, Egorova S, Musallam A, Hussain MS, Nejad P, Patel B, Hei H, Khoury S, Quintana F, Kivisakk P, Chitnis T, Weiner HL. Ann Neurol. 2013 Jun;73(6):729-40. PMID: 23494648.
  157. Increased Th17 response to myelin peptides in pediatric MS.
    Vargas-Lowy D, Kivisakk P, Gandhi R, Raddassi K, Soltany P, Gorman MP, Khoury SJ, Chitnis T. Clin Immunol. 2013 Mar;146(3):176-84. PMID: 23352968.
  158. Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosis.
    Healy BC, Engler D, Glanz B, Musallam A, Chitnis T. Mult Scler Int. 2013;2013:189624. PMID: 23555057; PMCID: PMC3608311.
  159. Evaluation of an online platform for multiple sclerosis research: patient description, validation of severity scale, and exploration of BMI effects on disease course.
    Bove R, Secor E, Healy BC, Musallam A, Vaughn T, Glanz BI, Greeke E, Weiner HL, Chitnis T, Wicks P, De Jager PL. PLoS One. 2013;8(3):e59707. PMID: 23527256; PMCID: PMC3603866.
  160. The impact of a recent relapse on patient-reported outcomes in subjects with multiple sclerosis.
    Healy BC, Degano IR, Schreck A, Rintell D, Weiner H, Chitnis T, Glanz BI. Qual Life Res. 2012 Dec;21(10):1677-84. PMID: 22237991.
  161. Work productivity in relapsing multiple sclerosis: associations with disability, depression, fatigue, anxiety, cognition, and health-related quality of life.
    Glanz, BI, Degano IR, Rintell DJ, Chitnis T, Weiner HL, Healy BC. Value Health. 2012 Dec;15(8):1029-35. PMID: 23244804.
  162. Effect of gender on late-onset multiple sclerosis.
    Bove RM, Healy B, Augustine A, Musallam A, Gholipour T, Chitnis T. Mult Scler. 2012 Oct;18(10):1472-9. PMID 22383227.
  163. The impact of lesion in-painting and registration methods on voxel-based morphometry in detecing regional cerebral gray matter atrophy in multiple sclerosis.
    Cecciarelli A, Jackson JS, Tauhid S, Arora A, Gorky J, Dell’Oglio E, Bakshi A, Chitnis T, Khoury SJ, Weiner HL, Guttmann CR, Bakshi R, Neema M. AJNR Am J Neuroradiol. 2012 Sep;33(8):1579-85. PMID: 22460341; PMCID: PMC3425668.
  164. An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity.
    Ottoboni L, Keenan BT, Tamayo P, Kuchroo M, Mesirov JP, Buckle GJ, Khoury SJ, Hafler DA, Weiner HL, De Jager PL. Sci Transl Med. 2012 Sep 26;4(153):153ra131. PMID: 23019656; PMCID: PMC3753678.
  165. Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: A longitudinal study.
    Moodie J, Healy BC, Buckle GJ, Gauthier SA, Glanz BI, Arora A, Ceccarelli A, Tauhid S, Han XM, Venkataraman A, Chitnis T, Khoury SJ, Guttmann CR, Weiner HL, Neema M, Bakshi R. J Neurol Sci. 2012 Apr 15;315(1-2):49-54. PMID: 22209496; PMCID: PMC22209496.
  166. CADASIL mutation and Balo concentric sclerosis: a link between demyelination and ischemia?
    Chitnis T, Hollmann TJ. Neurology. 2012 Jan 17;78(3):221-3. PMID: 22218279; PMCID: PMC3466606.
  167. Cognitive deterioration in patients with early multiple sclerosis: a 5-year study.
    Glanz BI, Healy BC, Hviid LE, Chitnis T, Weiner HL. J Neurol Neurosurg Psychiatry. 2012 Jan;83(1):38-43. PMID: 21746743.
  168. Improving power to detect disease progression in multiple sclerosis through alternative analysis strategies.
    Healy B, Chitnis T, Engler D. J Neurol. 2011 Oct; 258(10):1812-9. PMID: 21472497.
  169. Patient reported outcomes in benign multiple sclerosis.
    Hviid L, Healy B, Rintell D, Chitnis T, Weiner H, Glanz B. J Mult Scler. 2011 Jul;17(7):876-84. PMID: 21372114.
  170. Demographic and clinical characteristics of malignant multiple sclerosis.
    Gholipour T, Healy B, Baruch NF, Weiner HL, Chitnis T. Neurology. 2011 Jun 7;76(23):1996-2001.PMID: 21646626.
  171. Brain MRI Lesion Load at 1.5T and 3T versus Clinical Status in Multiple Sclerosis.
    Stankiewicz JM, Glanz BI, Healy BC, Arora A, Neema M, Benedict RH, Guss ZD, Tauhid S, Buckle GJ, Houtchens MK, Khoury SJ, Weiner HL, Guttmann CR, Bakshi R. J Neuroimaging. 2011 Apr;21(2):e50-6. PMID: 19888926; PMCID: PMC3043123.
  172. Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis.
    Healy BC, Engler D, Gholipour T, Weiner H, Bakshi R, Chitnis T. J Neurol Sci. 2011 Apr 15;303(1-2):109-13. PMID: 21251671.
  173. Population structure and HLA DRB1*1501 in the response of subjects with multiple sclerosis to first-line treatments.
    Gross R, Healy BC, Cepok S, Chitnis T, Khoury SJ, Hemmer B, Weiner HL, Hafler DA, De Jager PL. J Neuroimmunol. 2011 Apr;233(1-2):168-74. PMID: 21115201.
  174. A method for evaluating treatment switching criteria in multiple sclerosis.
    Healy BC, Glanz BI, Stankiewicz J, Buckle G, Weiner H, Chitnis T. Mult Scler. 2010  Dec;16(12):1483-9. PMID: 20736245.
  175. A putative Alzheimer's disease risk allele in PCK1 influences brain atrophy in multiple sclerosis.
    Xia Z, Chibnik LB, Glanz BI, Liguori M, Shulman JM, Tran D, Khoury SJ, Chitnis T, Holyoak T, Weiner HL, Guttmann CR, De Jager PL. PLoS One. 2010 Nov 30;5(11):e14169. PMID: 21152065; PMCID: PMC2994939
  176. A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis.
    Khoury SJ, Healy BC, Kivisäkk P, Viglietta V, Egorova S, Guttmann CR, Wedgwood JF, Hafler DA, Weiner HL, Buckle G, Cook S, Reddy S. Arch Neurol. 2010 Sep;67(9):1055-6. PMID: 20837847; PMCID: PMC2954052.
  177. Seasonal prevalence of MS disease activity.
    Meier DS, Balashov KE, Healy B, Weiner HL, Guttmann CR. Neurology. 2010 Aug 31;75(9):799-806. PMID: 20805526; PMCID: PMC2938966.
  178. HLA B*44: protective effects in MS susceptibility and MRI outcome measures.
    Healy BC, Liguori M, Tran D, Chitnis T, Glanz B, Wolfish C, Gauthier S, Buckle G, Houtchens M, Stazzone L, Khoury S, Hartzmann R, Fernandez-Vina M, Hafler DA, Weiner HL, Guttmann CR, De Jager PL. Neurology. 2010 Aug 17;75(7):634-40. PMID: 20713950; PMCID: PMC2931768.
  179. The association between cognitive impairment and quality of life in patients with early multiple sclerosis.
    Glanz BI, Healy BC, Rintell DJ, Jaffin SK, Bakshi R, Weiner HL. J Neurol Sci. 2010 Mar 15;290(1-2):75-9. PMID: 19944429.
  180. Regional white matter atrophy–based classification of multiple sclerosis in cross-sectional and longitudinal data.
    Sampat MP, Berger AM, Healy BC, Hildenbrand P, Vass J, Meier DS, Chitnis T, Weiner HL, Bakshi R, Guttmann CR. AJNR Am J Neuroradiol. 2009 Oct;30(9):1731-9. PMID: 19696139; PMCID: PMC2821733.
  181. Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study.
    Gauthier SA, Glanz BI, Mandel M, Tsagkaropoulos A, Neema M, Stankiewicz J, Arora A, Duan Y, Liptak Z, Egorova S, Buckle GJ, Bakshi R, Guttmann CR, Khoury SJ, Weiner HL. J Neurol Sci. 2009 Sep 15;284(1-2):116-9. PMID: 19428028.
  182. Smoking and disease progression in multiple sclerosis.
    Healy BC, Ali EN, Guttmann CR, Chitnis T, Glanz BI, Buckle G, Houtchens M, Stazzone L, Moodie J, Berger AM, Duan Y, Bakshi R, Khoury S, Weiner H, Ascherio A. Arch Neurol. 2009 Jul;66(7):858-64. PMID: 19597087; PMCID: PMC2754172.
  183. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells.
    Kivisäkk P, Healy BC, Viglietta V, Quintana FJ, Hootstein MA, Weiner HL, Khoury SJ. Neurology. 2009 Jun 2;72(22):1922-30. PMID: 19487650; PMCID: PMC2690969.
  184. Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States.
    Chitnis T, Glanz B, Jaffin S, Healy B. Mult Scler. 2009 May;15(5):627-31. PMID: 19299440.
  185. Spinal cord lesions and clinical status in multiple sclerosis: A 1.5 T and 3 T MRI study.
    Stankiewicz JM, Neema M, Alsop DC, Healy BC, Arora A, Buckle GJ, Chitnis T, Guttmann CR, Hackney D, Bakshi R. J Neurol Sci. 2009 Apr 15;279(1-2):99-105. PMID: 19178916; PMCID: PMC2679653
  186. Rate of brain atrophy in benign vs early multiple sclerosis.
    Gauthier SA, Berger AM, Liptak Z, Duan Y, Egorova S, Buckle GJ, Glanz BI, Khoury SJ, Bakshi R, Weiner HL, Guttmann CR.  Arch Neurol. 2009 Feb;66(2):234-7.  PMID: 19204160.
  187. Daclizumab in treatment of multiple sclerosis patients.
    Ali EN, Healy BC, Stazzone LA, Brown BA, Weiner HL, Khoury SJ. Mult Scler. 2009 Feb;15(2):272-4. PMID: 19136546.
  188. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis.
    Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Arch Neurol. 2009 Jan;66(1):54-9. PMID: 19139299
  189. Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis.
    Neema M, Arora A, Healy BC, Guss ZD, Brass SD, Duan Y, Buckle GJ, Glanz BI, Stazzone L, Khoury SJ, Weiner HL, Guttmann CR, Bakshi R. J Neuroimaging. 2009 Jan;19(1):3-8. PMID: 19192042; PMCID: PMC2762230.
  190. Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale.
    Bakshi R, Neema M, Healy BC, Liptak Z, Betensky RA, Buckle GJ, Gauthier SA, Stankiewicz J, Meier D, Egorova S, Arora A, Guss ZD, Glanz B, Khoury SJ, Guttmann CR, Weiner HL.  Arch Neurol. 2008 Nov;65(11):1449-53. PMID: 19001162; PMCID: PMC2762216.
  191. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial.
    Viglietta V, Bourcier K, Buckle GJ, Healy B, Weiner HL, Hafler DA, Egorova S, Guttmann CR, Rusche JR, Khoury SJ. Neurology. 2008 Sep 16;71(12):917-24. PMID: 18794494.
  192. Medulla oblongata volume: a biomarker of spinal cord damage and disability in multiple sclerosis.
    Liptak Z, Berger AM, Sampat MP, Charil A, Felsovalyi O, Healy BC, Hildenbrand P, Khoury SJ, Weiner HL, Bakshi R, Guttmann CR. AJNR Am J Neuroradiol. 2008 Sep;29(8):1465-70. PMID: 18556361.
  193. Estimating Time to Event From Longitudinal Categorical Data: An Analysis of Multiple Sclerosis Progression.
    Mandel M, Gauthier SA, Guttmann CR, Weiner HL, Betensky RA. J Am Stat Assoc. 2007 Dec;102(480):1254-1266. PMID: 19081806; PMCID: PMC2600443.
  194. Predicting short-term disability in multiple sclerosis.
    Gauthier SA, Mandel M, Guttmann CR, Glanz BI, Khoury SJ, Betensky RA, Weiner HL. Predicting short-term disability in multiple sclerosis. Neurology. 2007 Jun 12;68(24):2059-65. PMID: 17562826.
  195. A model for the comprehensive investigation of a chronic autoimmune disease: the mulitple sclerosis CLIMB study.
    Gauthier SA, Glanz BI, Mandel M, Weiner HL. Autoimmun Rev. 2006 Oct;5(8):532-6. Review. PMID: 17027888.